Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors
Journal of Medicinal Chemistry · 25.12.2025 · 68 (24) · 25899-25911
DOI: 10.1021/acs.jmedchem.5c01552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.12.2025. Verfasst von Yutaro Miura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kandasurugadai, Chiyoda-ku, Toky…. Hauptthemen laut MEDLINE: CD4 Antigens, HIV-1, Immunoconjugates, Antibodies, Neutralizing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The development of new anti-HIV drugs with a novel mechanism of action is still required. A human cell surface protein, CD4, is a primary receptor for HIV-1 entry, and we have developed small-molecule CD4-competitive HIV-1 entry inhibitors, including CD4 mimics. CD4 mimics bind to a viral envelope protein, gp120, and cause a conformational change. Combinational use of CD4 mimics with CD4-induced antibodies, which recognize the exposed regions of gp120 induced by the CD4/CD4 mimic binding, shows a synergistic effect of anti-HIV activity. Therefore, we envisioned that antibody-drug conjugates (ADCs) of CD4 mimics and CD4-induced antibodies would effectively inhibit virus entry. Herein, ADCs of CD4 mimics and CD4-induced antibodies were designed and synthesized, and their anti-HIV-1 activities were evaluated. As a result, several synthesized ADCs exhibited 7- to 10-fold higher anti-HIV-1 activity than that of the parent antibodies, although there remains significant room for improvement in these ADCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062, Japan.
- Collaborative Research Program with the Chemo-Sero-Therapeutic Research Institute for Anti-viral Agents and Hematological Diseases, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 5-1 Oe Honma…
ORCID-Profile: Kohei Tsuji, Hirokazu Tamamura
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Support for Pioneering Research Initiated by the Next Generation
Zitieren
APA
Miura, Y., Tsuji, K., Kobayakawa, T., Matsumoto, K., Kuwata, T., Matsuzaki, R., Matsushita, S., & Tamamura, H. (2025). Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors. Journal of Medicinal Chemistry, 68(24), 25899-25911. https://doi.org/10.1021/acs.jmedchem.5c01552
Vancouver
Miura Y, Tsuji K, Kobayakawa T, Matsumoto K, Kuwata T, Matsuzaki R, et al. Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors. Journal of Medicinal Chemistry. 2025;68(24):25899-25911. doi:10.1021/acs.jmedchem.5c01552
BibTeX
@article{Miura2025,
author = {Miura, Yutaro and Tsuji, Kohei and Kobayakawa, Takuya and Matsumoto, Kaho and Kuwata, Takeo and Matsuzaki, Riku and Matsushita, Shuzo and Tamamura, Hirokazu},
title = {Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {24},
pages = {25899--25911},
doi = {10.1021/acs.jmedchem.5c01552}
}
EUVIMED